NCT01570556

Brief Summary

When considering occult infections during the diagnostic workup of inflammation in Hemodialysis (HD) patients, the urine-deprived bladder is frequently dismissed as potential site of infection. The urinary tract, even in end stage renal disease (ESRD) patients on hemodialysis may represent a significant reservoir for infection. Delayed diagnosis is a relevant issue because the urinary tract is often overlooked as a source of infection in dialysis patients, especially because of absence of urinary tract infection (UTI) symptoms in HD patients. Contributing factors to asymptomatic UTI in HD patients include the presence of low urine volume, bladder stasis, and the fact that UTI symptoms are mostly related to voiding, which is reduced or absent in these patients. Persistence of asymptomatic bacteriuria and UTI may be related to higher levels of inflammatory markers in HD population. In view of the association between cardiovascular disease and cardio-vascular and all-cause mortality with inflammation, as expressed by elevated CRP and/or IL-6 levels in HD patients, the investigators questioned whether presence of asymptomatic UTI could contribute to elevated levels of inflammatory markers in patients with ESRD on maintenance HD therapy. Such a finding would provide a potential link between a treatable infection and a potential cardiovascular risk factor in this population.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 15, 2012

Completed
20 days until next milestone

First Posted

Study publicly available on registry

April 4, 2012

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Last Updated

April 4, 2012

Status Verified

March 1, 2012

Enrollment Period

2 years

First QC Date

March 15, 2012

Last Update Submit

April 3, 2012

Conditions

Keywords

HemodialysisInflammationBacteriuriaInterleukin 6C reactive protein

Outcome Measures

Primary Outcomes (1)

  • Change in serum inflammatory markers (CRP, IL-6)

    3 months, 6 months, and 12 months

Secondary Outcomes (1)

  • Cardio-vascular events

    3 months, 6 months and 12 months

Study Arms (2)

Patients with positive culture, treatment group

ACTIVE COMPARATOR

These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.

Other: Antibiotic treatment

Patients with positive culture, observation only

NO INTERVENTION

These asymptomatic patients with positive urine culture, will be observed only during the study period.

Interventions

In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.

Patients with positive culture, treatment group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female, age \> 18 years, in chronic hemodialysis treatment at least 3 months
  • Stable and adequate hemodialysis treatment three months prior to participation in study as defined by Kt/V \> 1.2 and hemodialysis performed at least 3 times weekly
  • Patients with native A-V Fistula or graft
  • Informed consent obtained before any trial-related activities

You may not qualify if:

  • Patients with an indwelling catheters
  • Patients with periodontitis
  • Patients with diabetic foot
  • Patients with active malignant disease or liver cirrhosis
  • Patients on chronic treatment with steroids on doses \> 10 mg/day Prednisone (or equivalent)
  • Patients treated with immunosuppressive agents
  • Patients suffering from
  • Acute vasculitis
  • Severe systemic infections
  • Heart failure (NYHA class III-IV)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nephrology Department, Assaf Harofeh Medical Center

Ẕerifin, 70300, Israel

RECRUITING

Related Publications (1)

  • Beberashvili I, Sinuani I, Azar A, Yasur H, Shapiro G, Feldman L, Averbukh Z, Weissgarten J. IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011 Sep;6(9):2253-63. doi: 10.2215/CJN.01770211. Epub 2011 Aug 18.

    PMID: 21852667BACKGROUND

MeSH Terms

Conditions

InflammationBacteriuria

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsUrinary Tract InfectionsInfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 15, 2012

First Posted

April 4, 2012

Study Start

December 1, 2011

Primary Completion

December 1, 2013

Last Updated

April 4, 2012

Record last verified: 2012-03

Locations